Medizone International (MZEIQ) 10-Q 13 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 13, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Medizone International Inc
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		359,434,068
Amendment Flag	false
Entity Central Index Key	753,772
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	[1]
Current Assets:
Cash	$ 120,200	$ 140,496
Inventory	198,623	265,234
Prepaid expenses	102,831	60,705
Total Current Assets	421,654	466,435
Property and equipment, net	518	830
Other Assets:
Trademark and patents, net	186,578	208,073
Lease deposit	4,272	4,272
Total Other Assets	190,850	212,345
Total Assets	613,022	679,610
Current Liabilities:
Accounts payable	469,468	470,147
Accounts payable – related parties	233,109	233,109
Accrued expenses	541,520	516,434
Accrued expenses – related parties	1,928,659	1,928,659
Customer deposits	30,000	30,000
Other payables	224,852	224,852
Notes payable	382,689	298,241
Total Current Liabilities	3,810,297	3,701,442
Stockholders’ Deficit:
Preferred stock, $0.00001 par value: 50,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 395,000,000 shares authorized; 359,434,068 and 346,034,068 shares outstanding, respectively	359,434	346,034
Additional paid-in capital	31,437,346	30,052,656
Accumulated other comprehensive loss	(39,487)	(58,098)
Accumulated deficit	(34,954,568)	(33,362,424)
Total Stockholders’ Deficit	(3,197,275)	(3,021,832)
Total Liabilities and Stockholders’ Deficit	$ 613,022	$ 679,610
[1]	The condensed consolidated balance sheet as of December 31, 2014 has been prepared using information from the audited consolidated balance sheet as of that date.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2015	Dec. 31, 2014	[1]
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	395,000,000	395,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares outstanding	359,434,068	346,034,068
[1]	The condensed consolidated balance sheet as of December 31, 2014 has been prepared using information from the audited consolidated balance sheet as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues	$ 167,000	$ 0	$ 167,000	$ 0
Operating Expenses:
Cost of revenues	88,411	0	88,411	0
General and administrative	800,185	429,900	1,401,199	1,164,435
Research and development	56,263	96,660	210,336	313,153
Depreciation and amortization	13,457	12,391	39,760	36,473
Total Operating Expenses	958,316	538,951	1,739,706	1,514,061
Loss from Operations	(791,316)	(538,951)	(1,572,706)	(1,514,061)
Interest expense	(6,820)	(6,192)	(19,438)	(18,651)
Net Loss	(798,136)	(545,143)	(1,592,144)	(1,532,712)
Other comprehensive gain (loss) on foreign currency translation	(1,051)	(6,290)	18,611	(3,872)
Total Comprehensive Loss	$ (799,187)	$ (551,433)	$ (1,573,533)	$ (1,536,584)
Basic and Diluted Net Loss per Common Share (in Dollars per share)	$ 0	$ 0	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding (in Shares)	358,036,242	338,259,689	352,368,867	333,532,440

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015		Sep. 30, 2014
Cash Flows from Operating Activities:
Net loss	$ (1,592,144)		$ (1,532,712)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	39,760		36,473
Stock-based compensation expense	722,090		394,520
Changes in operating assets and liabilities:
Prepaid expenses	7,838		7,921
Inventory	66,611		0
Accounts payable and accounts payable – related parties	(677)		(15,257)
Accrued expenses and accrued expenses – related parties	25,086		(11,659)
Net Cash Used in Operating Activities	(731,436)		(1,120,714)
Cash Flows from Investing Activities:
Purchase of patents	(17,955)		(29,246)
Net Cash Used in Investing Activities	(17,955)		(29,246)
Cash Flows from Financing Activities:
Principal payments on notes payable	(40,516)		(51,841)
Issuance of notes payable	75,000		0
Issuance of common stock	676,000		1,222,250
Net Cash Provided by Financing Activities	710,484		1,170,409
Effect of Foreign Currency Exchange Rates	18,611		(3,872)
Net increase (decrease) in cash	(20,296)		16,577
Cash as of beginning of the period	140,496	[1]	81,856
Cash as of end of the period	120,200		98,433
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	1,006		909
NON-CASH FINANCING ACTIVITIES:
Financing of insurance policies	$ 49,964		$ 65,214
[1]	The condensed consolidated balance sheet as of December 31, 2014 has been prepared using information from the audited consolidated balance sheet as of that date.

NOTE 1 BASIS OF PRESENTATION

NOTE 1 BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2015
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	NOTE 1 BASIS OF PRESENTATION The financial information of Medizone International, Inc. and subsidiaries (collectively, the Company) included herein is unaudited and has been prepared consistent with U.S. generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2014. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year.

NOTE 2 CANADIAN FOUNDATION FOR

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH	9 Months Ended
	Sep. 30, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible. Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate its financial statements with those of the VIE. The Company determined that CFGH met the requirements of a VIE effective upon the first advance to CFGH in 2009. Accordingly, the financial statements of CFGH have been consolidated with those of the Company for all periods presented.

NOTE 3 BASIC AND DILUTED NET LO

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: For the Three Months Ended September 30, 2015 2014 Numerator: Net loss $ (798,136 ) $ (545,143 ) Denominator: Weighted average number of common shares outstanding 358,036,242 338,259,689 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) For the Nine Months Ended September 30, 2015 2014 Numerator: Net loss $ (1,592,144 ) $ (1,532,712 ) Denominator: Weighted average number of common shares outstanding 352,368,867 333,532,440 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented.

NOTE 4 GOING CONCERN

NOTE 4 GOING CONCERN	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 4 GOING CONCERN The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred significant losses from its inception through September 30, 2015, which have resulted in an accumulated deficit of $34,954,568 as of September 30, 2015. The Company does not have funds sufficient to cover its operating costs for the next 12 months, has a working capital deficit of $3,388,643, and has relied exclusively on debt and equity financing. Accordingly, there is substantial doubt about its ability to continue as a going concern. Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations. The Company will require substantial additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional funding, it will be forced to substantially reduce or cease operations. The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes. During 2014, the Company raised a total of $1,604,250 through the sale of 23,978,572 shares of common stock at prices ranging from $0.05 to $0.085 per share, which funds have been used to keep the Company current in its public reporting obligations and to pay certain other corporate obligations including the costs of development for its hospital disinfection system. During the nine months ended September 30, 2015, the Company raised a total of $676,000 through the sale of 13,400,000 shares of common stock at prices ranging from $0.05 to $0.07 per share. The Company believes it will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2015, although there can be no assurance that these investors will purchase additional shares. The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

NOTE 5 COMMITMENTS AND CONTINGE

NOTE 5 COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 5 COMMITMENTS AND CONTINGENCIES The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters, will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows. Litigation Rakas vs. Medizone International, Inc Other Payables As of September 30, 2015 and December 31, 2014, the Company has $224,852 of past due payables for which the Company has not received invoices or demands for over 10 years. Although management of the Company does not believe that the amounts will be required to be paid, the amounts are recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired. Operating Leases The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform. The lease term is month-to-month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). Leases for a second laboratory space for full scale room testing and a storage unit are on a month-to-month basis with monthly lease payments of CD$1,375 and CD$475, respectively, plus the applicable GST. The Company has a corporate office lease with monthly payments of approximately $2,300 through December 31, 2015.

NOTE 6 COMMON STOCK OPTIONS

NOTE 6 COMMON STOCK OPTIONS	9 Months Ended
	Sep. 30, 2015
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 6 COMMON STOCK OPTIONS In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to a consultant for distribution channel related services to be performed. Options totaling 550,000 shares have vested as of September 30, 2015 and the remaining options will vest on the date certified by the Company as the date that certain other milestones are achieved. The options have an exercise price of $0.17 per share, and are exercisable for up to five years. The Company recognized no expense in connection with these options during the nine months ended September 30, 2015 and 2014. The Company will measure and begin recognizing the remaining expense, when the achievement of the required milestones becomes probable. In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant. These options are exercisable at $0.10 per share for five years from the date of grant and are fully vested as of September 30, 2015. The Company recognized expense of $17,660 during the nine months ended September 30, 2015, as the required milestones were achieved. On February 26, 2014, the Company granted to a new director options for the purchase of 2,000,000 shares of common stock, with an exercise price of $0.1095 per share. Of these options, 1,000,000 vested on February 26, 2015 and the remaining 1,000,000 options will vest upon the successful achievement of certain milestones. Unvested options vest immediately in the event of a change in control of the Company. The options are exercisable for five years. The grant date fair value of the options was $192,184. The Company recognized $16,017 and $56,053 of expense during the nine months ended September 30, 2015 and 2014, respectively, and are fully vested as of September 30, 2015. Also, the Company will recognize an expense totaling $96,092 when the achievement of the required milestones becomes probable. On February 26, 2014, the Company granted options to six consultants and service providers for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.1095 per share. Options for 200,000 shares vested immediately upon grant and options for the remaining 50,000 shares vested on January 9, 2015. The options are exercisable for five years. The grant date fair value of these options was $24,023. The Company recognized expense of $800 and $22,822 during the nine months ended September 30, 2015 and 2014, respectively. The options were fully vested on January 9, 2015. On April 30, 2014, the Company granted options for the purchase of a total of 1,350,000 shares of common stock for services rendered, as follows: 250,000 shares to each of four directors of the Company, 100,000 shares to each of two consultants, and 75,000 shares each to a consultant and an employee of the Company. All options vested upon grant, have an exercise price of $0.163 per share, and are exercisable for up to five years. The total value of these options at the date of grant was $193,234, which the Company recognized as an expense during the nine months ended September 30, 2014. On May 6, 2014, the Company granted options to a consultant for the purchase of 100,000 shares of common stock at an exercise price of $0.19 per share. Options for 50,000 shares vested immediately upon grant and options for the remaining 50,000 shares vested during the nine months ended September 30, 2015. The options are exercisable for five years. The grant date fair value of these options was $16,684. The Company recognized expense of $8,342 each during the nine months ended September 30, 2015 and 2014. On August 15, 2014, the Company granted options to a consultant for the purchase of 75,000 shares of common stock at an exercise price of $0.13 per share. The shares will vest when certain required milestones are achieved. The options are exercisable for five years. The grant date fair value of these options was $8,555. The Company will recognize an expense when the achievement of the required milestones becomes probable. On August 15, 2014, the Company granted options for services rendered to a director of the Company for the purchase of 1,000,000 shares of common stock at an exercise price of $0.13 per share. These options vested immediately upon grant. The Company recognized expense of $114,069 during the nine months ended September 30, 2014, which was the grant date fair value of these options. On October 7, 2014, the Company granted to a new board member options for the purchase of 1,000,000 shares of common stock, with an exercise price of $0.16 per share. These options vested on October 7, 2015. Unvested options vest immediately in the event of a change in control of the Company. The options are exercisable for five years from the date of grant. The grant date fair value of the options was $140,178. The Company recognized $105,133 of expense in connection with these options during the nine months ended September 30, 2015. On December 4, 2014, the Company granted options to four consultants for the purchase of a total of 140,000 shares of common stock at an exercise price of $0.11 per share. These options have vested as of September 30, 2015. The options have an exercise price of $0.11 per share, and are exercisable for up to five years from the date of grant. The Company recognized $13,462 of expense in connection with these options during the nine months ended September 30, 2015. In August 2015, the Company granted options for the purchase of a total of 7,150,000 shares of common stock for services rendered, as follows: 6,000,000 shares total to five directors of the Company, 650,000 shares total to four consultants, and 500,000 shares to an employee of the Company. All options vested upon grant, have an exercise price of $0.088 per share, and are exercisable for up to five years. The total value of these options at the date of grant was $541,686, which the Company recognized as an expense during the nine months ended September 30, 2015. In August 2015, the Company granted options to a consultant for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.085 per share. These options vested upon grant and are exercisable for up to five years. The total value of these options at the date of grant was $18,943, which the Company recognized as an expense during the nine months ended September 30, 2015. The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions: Risk-free interest rate 1.52% to 1.60 % Expected life 5 years Expected volatility 131.33% to 136.34 % Dividend yield 0.00 % A summary of the status of the Company’s outstanding options as of September 30, 2015 and for the nine months then ended, is presented below: Shares Weighted Average Exercise Price Outstanding, beginning of the period 18,565,000 $ 0.180 Granted 7,400,000 0.088 Expired/Canceled (5,000,000 ) 0.207 Exercised - - Outstanding, end of the period 20,965,000 0.221 Exercisable 18,440,000 0.240 The Company estimates the fair value of each stock option award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $722,090 and $394,520 related to stock options was recorded for the nine months ended September 30, 2015 and 2014, respectively. The Company will recognize this expense as these options vest over their remaining useful lives, which range from 2 to 47 months.

NOTE 7 STOCK TRANSACTIONS AND S

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS During August 2015, the Company sold an aggregate of 2,600,000 restricted shares of common stock to five accredited investors for cash proceeds totaling $130,000, or $0.05 per share. During April, May and June 2015, the Company sold an aggregate of 7,500,000 restricted shares of common stock to eight accredited investors for cash proceeds totaling $375,000, or $0.05 per share. During February and March 2015, the Company sold an aggregate of 3,000,000 restricted shares of common stock to seven accredited investors for cash proceeds totaling $150,000, or $0.05 per share. During February 2015, the Company sold 300,000 restricted shares of common stock to an accredited investor for cash proceeds totaling $21,000, or $0.07 per share. During January, February and March 2014, the Company sold an aggregate of 9,000,000 restricted shares of common stock to five accredited investors for cash proceeds totaling $450,000, or $0.05 per share. During March 2014, the Company sold an aggregate of 7,050,000 restricted shares of common stock to 16 accredited investors for cash proceeds totaling $599,250, or $0.085 per share. During September 2014, the Company sold an aggregate of 2,471,429 restricted shares of common stock to five accredited investors for cash proceeds totaling $173,000, or $0.07 per share.

NOTE 8 ACCOUNTS PAYABLE - RELAT

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 ACCOUNTS PAYABLE – RELATED PARTIES As of September 30, 2015 and December 31, 2014, the Company had accounts payable of $233,109, owed to certain consultants for services rendered in prior years. These consultants are stockholders of the Company.

NOTE 9 RECENT ACCOUNTING PRONOU

NOTE 9 RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 9 RECENT ACCOUNTING PRONOUNCEMENT In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs.” In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

NOTE 10 NOTES PAYABLE

NOTE 10 NOTES PAYABLE	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 10 NOTES PAYABLE During September 2015, the Company entered into two notes payable with an unrelated third party which total $75,000. The notes are unsecured, have maturity dates in September 2018, bear interest of 12.0% per annum, with interest only payments due July 5 and January 5 each year through maturity. The holder may convert up to 20 percent of the then outstanding principal of the notes into conversion shares at $0.10 per share, at any time prior to the payment in full of the outstanding principle balance of the notes. The Company has the right to prepay these notes without premium or penalty at any time.

NOTE 11 SUBSEQUENT EVENTS

NOTE 11 SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 11 SUBSEQUENT EVENTS The Company has evaluated subsequent events through the filing date of this Quarterly Report on Form 10-Q and no such events require accounting or disclosure in the accompanying financial statements.

NOTE 3 BASIC AND DILUTED NET 17

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: For the Three Months Ended September 30, 2015 2014 Numerator: Net loss $ (798,136 ) $ (545,143 ) Denominator: Weighted average number of common shares outstanding 358,036,242 338,259,689 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) For the Nine Months Ended September 30, 2015 2014 Numerator: Net loss $ (1,592,144 ) $ (1,532,712 ) Denominator: Weighted average number of common shares outstanding 352,368,867 333,532,440 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 )

NOTE 6 COMMON STOCK OPTIONS (Ta

NOTE 6 COMMON STOCK OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions: Risk-free interest rate 1.52% to 1.60 % Expected life 5 years Expected volatility 131.33% to 136.34 % Dividend yield 0.00 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the status of the Company’s outstanding options as of September 30, 2015 and for the nine months then ended, is presented below: Shares Weighted Average Exercise Price Outstanding, beginning of the period 18,565,000 $ 0.180 Granted 7,400,000 0.088 Expired/Canceled (5,000,000 ) 0.207 Exercised - - Outstanding, end of the period 20,965,000 0.221 Exercisable 18,440,000 0.240

NOTE 2 CANADIAN FOUNDATION FO19

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH (Details)	12 Months Ended
	Dec. 31, 2008
Disclosure Text Block [Abstract]
Variable Interest Entity, Qualitative or Quantitative Information, Purpose of VIE	(1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

NOTE 3 BASIC AND DILUTED NE

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule of Earnings Per Share, Basic and Diluted [Abstract]
Numerator: Net loss	$ (798,136)	$ (545,143)	$ (1,592,144)	$ (1,532,712)
Denominator: Weighted average number of common shares outstanding	358,036,242	338,259,689	352,368,867	333,532,440
Basic and diluted net loss per common share	$ 0	$ 0	$ 0	$ 0

NOTE 4 GOING CONCERN (Details)

NOTE 4 GOING CONCERN (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
NOTE 4 GOING CONCERN (Details) [Line Items]
Retained Earnings (Accumulated Deficit)	$ (34,954,568)		$ (33,362,424)	[1]
Working capital (deficit)	$ (3,388,643)
Going Concern Note	The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes.
Proceeds from Issuance of Common Stock	$ 676,000	$ 1,222,250	$ 1,604,250
Stock Issued During Period, Shares, New Issues	13,400,000		23,978,572
Minimum [Member]
NOTE 4 GOING CONCERN (Details) [Line Items]
Sale of Stock, Price Per Share	$ 0.05		$ 0.05
Maximum [Member]
NOTE 4 GOING CONCERN (Details) [Line Items]
Sale of Stock, Price Per Share	$ 0.07		$ 0.085
[1]	The condensed consolidated balance sheet as of December 31, 2014 has been prepared using information from the audited consolidated balance sheet as of that date.

NOTE 5 COMMITMENTS AND CONTIN22

NOTE 5 COMMITMENTS AND CONTINGENCIES (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2015CAD	Dec. 31, 2002USD ($)	Dec. 31, 2001USD ($)	Dec. 31, 2014USD ($)
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Accounts Payable, Current	$ 469,468				$ 470,147	[1]
Accounts Payable, Other, Current	224,852				224,852	[1]
Certified Laboratory Space [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals | CAD		CAD 1,375
Second Laboratory for Full Scale Room Testing [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals | CAD		1,375
Full Scale Room Testing [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals | CAD		CAD 475
Corporate Offices [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	2,300
Settlement Amount, September 2001 [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Litigation Settlement, Amount				$ 25,000
Default Judgement [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Accounts Payable, Current	143,000				143,000
Default Judgement [Member] | Settlement Amount, January 2002 [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought, Value			$ 143,000
Litigation Fees [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Accounts Payable, Current	$ 21,308				$ 21,308
[1]	The condensed consolidated balance sheet as of December 31, 2014 has been prepared using information from the audited consolidated balance sheet as of that date.

NOTE 6 COMMON STOCK OPTIONS (De

NOTE 6 COMMON STOCK OPTIONS (Details)	Dec. 04, 2014$ / sharesshares	Oct. 07, 2014USD ($)$ / sharesshares	Aug. 15, 2014USD ($)$ / sharesshares	May. 06, 2014USD ($)$ / sharesshares	Apr. 30, 2014$ / sharesshares	Feb. 26, 2014USD ($)$ / sharesshares	Aug. 31, 2015$ / sharesshares	Aug. 31, 2013$ / sharesshares	May. 31, 2012$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										7,400,000
Share-based Compensation (in Dollars) | $										$ 722,090	$ 394,520
May 2012 [Member] | Non-Employee Stock Option [Member] | Options Granted for Distribution Channel Related Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares										550,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares									$ 0.17
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period									5 years
Share-based Compensation (in Dollars) | $										$ 0	0
August 2013 [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								250,000		17,660
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares								$ 0.10
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								5 years
February 2014 [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						250,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares						$ 0.1095
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						5 years
Share-based Compensation (in Dollars) | $										$ 800	22,822
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | $						$ 24,023
Number of consultants and service providers issued options						6
February 2014 [Member] | Employee Stock Option [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						2,000,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares						$ 0.1095
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						5 years
Share-based Compensation (in Dollars) | $										16,017	56,053
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | $						$ 192,184
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $										96,092
February 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						200,000
February 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | Employee Stock Option [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						1,000,000
February 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						50,000
February 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | Employee Stock Option [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						vest upon the successful achievement of certain milestones
April 30, 2014 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					1,350,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares					$ 0.163
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					5 years
Share-based Compensation (in Dollars) | $											193,234
April 30, 2014 [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					250,000
April 30, 2014 [Member] | Director Two [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					250,000
April 30, 2014 [Member] | Director Three [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					250,000
April 30, 2014 [Member] | Director Four [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					250,000
April 30, 2014 [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Number of consultants and service providers issued options					2
April 30, 2014 [Member] | Non-Employee Stock Option [Member] | Consultant [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					100,000
April 30, 2014 [Member] | Non-Employee Stock Option [Member] | Consultant Two [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					100,000
April 30, 2014 [Member] | Non-Employee Stock Option [Member] | Consultant Three [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					75,000
April 30, 2014 [Member] | Non-Employee Stock Option [Member] | Employee [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					75,000
April 30, 2014 [Member] | Employee Stock Option [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Number of directors issued options					4
May 6, 2014 [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				100,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares				$ 0.19
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				5 years
Share-based Compensation (in Dollars) | $										8,342	8,342
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | $				$ 16,684
May 6, 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				50,000
May 6, 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				50,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				vested immediately upon grant and options for the remaining 50,000 shares vested during the nine months ended September 30, 2015.
August 15, 2014 [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			75,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares			$ 0.13
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | $			$ 8,555
August 15, 2014 [Member] | Employee Stock Option [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,000,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares			$ 0.13
Share-based Compensation (in Dollars) | $											$ 114,069
December 4, 2014 [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	140,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares	$ 0.11
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
Share-based Compensation (in Dollars) | $										13,462
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	The shares will vest when certain required milestones are achieved.
Number of consultants and service providers issued options	4
October 7, 2014 [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,000,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares		$ 0.16
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Share-based Compensation (in Dollars) | $										105,133
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		These options vested on October 7, 2015. Unvested options vest immediately in the event of a change in control of the Company.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | $		$ 140,178
August 2015 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							7,150,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years
Share-based Compensation (in Dollars) | $										$ 541,686
August 2015 [Member] | Non-Employee Stock Option [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							650,000			250,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares										$ 0.085
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years
Share-based Compensation (in Dollars) | $										$ 18,943
Number of consultants and service providers issued options							4
August 2015 [Member] | Employee Stock Option [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							500,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares							$ 0.088
August 2015 [Member] | Employee Stock Option [Member] | Director [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							6,000,000
Number of directors issued options							5
Minimum [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition										2 months
Maximum [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition										47 months

NOTE 6 COMMON STOCK OPTIONS

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options	9 Months Ended
	Sep. 30, 2015
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items]
Expected life	5 years
Dividend yield	0.00%
Minimum [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items]
Risk-free interest rate	1.52%
Expected volatility	131.33%
Maximum [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items]
Risk-free interest rate	1.60%
Expected volatility	136.34%

NOTE 6 COMMON STOCK OPTIO25

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Schedule of Share-Based Compensation, Stock Options, Activity [Abstract]
Outstanding, beginning of the period | shares	18,565,000
Outstanding, beginning of the period	$ 0.180
Granted | shares	7,400,000
Granted	$ 0.088
Expired/Canceled | shares	(5,000,000)
Expired/Canceled	$ 0.207
Exercised | shares	0
Exercised	$ 0
Outstanding, end of the period | shares	20,965,000
Outstanding, end of the period	$ 0.221
Exercisable | shares	18,440,000
Exercisable	$ 0.240

NOTE 7 STOCK TRANSACTIONS AND26

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details)	1 Months Ended				2 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended
	Aug. 31, 2015USD ($)$ / sharesshares	Feb. 28, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)shares	Mar. 31, 2014USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares	Sep. 30, 2015shares	Dec. 31, 2014shares
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares) | shares								13,400,000	23,978,572
Restricted Stock [Member]
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares) | shares	2,600,000	300,000	2,471,429		3,000,000	7,500,000
Number of Investors	5		5		7	8
Stock Issued During Period, Value, New Issues	$ 130,000		$ 173,000
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares	$ 0.05	$ 0.07		$ 0.05	$ 0.05	$ 0.05	$ 0.05
Proceeds from Issuance or Sale of Equity		$ 21,000	$ 0.07		$ 150,000	$ 375,000
Restricted Stock [Member] | Stock Issued January, February and March 2014 [Member]
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares) | shares							9,000,000
Number of Investors							5
Proceeds from Issuance or Sale of Equity							$ 450,000
Restricted Stock [Member] | Stock Issued March 2014 [Member]
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares) | shares				7,050,000
Number of Investors				16
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares				$ 0.085			$ 0.085
Proceeds from Issuance or Sale of Equity				$ 599,250

NOTE 8 ACCOUNTS PAYABLE - REL27

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Accounts Payable, Related Parties, Current	$ 233,109	$ 233,109	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2014 has been prepared using information from the audited consolidated balance sheet as of that date.

NOTE 10 NOTES PAYABLE (Details)

NOTE 10 NOTES PAYABLE (Details)	1 Months Ended
	Sep. 30, 2015USD ($)$ / shares
Debt Disclosure [Abstract]
Number of Notes Payable	2
Debt Instrument, Face Amount	$ 75,000
Debt Instrument, Maturity Date, Description	September 2,018
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Payment Terms	payments due July 5 and January 5 each year through maturity
Debt Instrument, Convertible, Terms of Conversion Feature	The holder may convert up to 20 percent of the then outstanding principal of the notes into conversion shares
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.10